WO2019221003A1 - Composition pour inhiber la prolifération de cellules cancéreuses, composition anticancéreuse, composition pour inhiber la cancérisation de cellules normales, composition pour inhiber l'apparition du cancer, et composition pour induire la mort de cellules cancéreuses - Google Patents

Composition pour inhiber la prolifération de cellules cancéreuses, composition anticancéreuse, composition pour inhiber la cancérisation de cellules normales, composition pour inhiber l'apparition du cancer, et composition pour induire la mort de cellules cancéreuses Download PDF

Info

Publication number
WO2019221003A1
WO2019221003A1 PCT/JP2019/018555 JP2019018555W WO2019221003A1 WO 2019221003 A1 WO2019221003 A1 WO 2019221003A1 JP 2019018555 W JP2019018555 W JP 2019018555W WO 2019221003 A1 WO2019221003 A1 WO 2019221003A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
cancer
tureronol
inhibiting
turmeronol
Prior art date
Application number
PCT/JP2019/018555
Other languages
English (en)
Japanese (ja)
Inventor
知夏 花房
有沙 不破
隆正 内尾
健吾 川▲崎▼
室山　幸太郎
室▲崎▼　伸二
Original Assignee
ハウスウェルネスフーズ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハウスウェルネスフーズ株式会社 filed Critical ハウスウェルネスフーズ株式会社
Priority to JP2020519595A priority Critical patent/JPWO2019221003A1/ja
Publication of WO2019221003A1 publication Critical patent/WO2019221003A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Non-patent Document 1 reports that turomerol A has an action of inhibiting soybean lipoxygenase enzyme activity and an antioxidant action.
  • Patent Document 1 describes the action of protein-binding polysaccharides isolated from turmeric rhizomes, and Non-Patent Document 1 describes the antioxidant action of turmeronol A.
  • turmeronol A and tureronol B derived from turmeric suppress cell canceration and malignant progression of cancer, that is, onset of cancer, or induce cancer cell death.
  • tureronol A and tureronol B can suppress cell canceration and malignant progression of cancer, that is, the onset of cancer, and can induce cancer cell death.
  • the inventor has completed the following present invention.
  • a composition for inhibiting the growth of cancer cells comprising at least one of tureronol A and tureronol B as an active ingredient.
  • the anticancer composition according to (3) which is an anticancer composition for colorectal cancer.
  • a composition for suppressing canceration of normal cells comprising at least one of tureronol A and tureronol B as an active ingredient.
  • the composition for suppressing canceration of normal cells according to (5) which suppresses canceration of normal cells to colorectal cancer.
  • a composition for suppressing the onset of cancer comprising at least one of turmonol A and turmonol B as an active ingredient.
  • the composition for suppressing the onset of cancer according to (7) which is a composition for suppressing the onset of cancer for colorectal cancer.
  • a composition for inducing cancer cell death comprising at least one of tureronol A and tureronol B as an active ingredient.
  • the composition for inducing cancer cell death according to (9), wherein the cancer cells are colon cancer cells.
  • the present invention relates to a composition for inhibiting cancer cell growth, a composition for anticancer, a composition for inhibiting canceration of normal cells, a cancer onset, comprising at least one of tureronol A and tureronol B as an active ingredient.
  • a composition for suppression and a composition for inducing cancer cell death are provided.
  • FIG. 1 shows the measurement results of the ability to suppress the metabolic activity of HT-29 cells, which are human colon cancer cell lines, by tureronol A.
  • FIG. 2 shows the measurement results of the ability to suppress the metabolic activity of HT-29 cells with tureronol B.
  • Tameronol A and Tameronol B are compounds having the following planar structures, respectively.
  • turmeronol A and turmeronol B separated from turmeric are each in the S-configuration at the 6-position carbon in the partial structure of 2-methyl-2-hepten-4-one.
  • turmeronol A and turmeronol B that can be used in the present invention are not limited to termeronol A and turmeronol B having a three-dimensional structure derived from turmeric, but preferably have the above planar structure.
  • Turmeronol A and turmeronol B having a three-dimensional structure derived from turmeric In the present invention, various forms of turmeronol A and tereronol B such as salts and hydrates can be used.
  • the turmeronol A and turmeronol B in the form of salt are not particularly limited as long as they are pharmaceutically acceptable salts, and examples thereof include sodium salts (sodium salts of phenolic hydroxyl groups).
  • the active ingredient is at least one of tureronol A and tureronol B. That is, the active ingredient may be composed only of turmonol A, may be composed only of turmonol B, or may be a mixture of turmonol A and turmonol B.
  • the active ingredient used in the present invention is more preferably derived from a plant raw material, more preferably from a ginger family turmeric genus.
  • Curcuma longa (turmeric), Curcuma aromatica, Curcuma zedoaria, Curcuma phaeocaulis, Curcuma kwangsiensis, Curcuma wenyu, Turmeronol A and turmeronol B can be obtained from sites such as rhizomes of plants belonging to the genus Turmeric.
  • the rhizome one collected from soil may be used, and an appropriate portion of the rhizome may be used as it is, cut into an appropriate size or shape, or pulverized.
  • the plant material may be appropriately dried.
  • Water includes hot water.
  • hot water for example, hot water of 95 ° C. or higher can be used.
  • the polar organic solvent include at least one alcohol (may be a mixed solvent of a plurality of alcohols).
  • the alcohol is not particularly limited, but methanol and ethanol are preferable.
  • the mixing ratio in the case of using a mixed solvent of alcohol and water as the extraction solvent is not particularly limited.
  • the weight ratio is preferably in the range of 10:90 to 90:10, and more preferably in the range of 20:80 to 50:50.
  • the extraction method of at least one selected from turmonol A and turmonol B from plants or plant processed products is not particularly limited.
  • the extract containing at least one selected from turmeronol A and turmeronol B is used after volatilizing and removing the extraction solvent as necessary.
  • the method for preparing at least one fraction having an increased purity selected from tureronol A and tureronol B from the extract is not particularly limited.
  • at least one selected from turmonol A and turmonol B is used.
  • the compound-containing extract is subjected to ethyl acetate / water liquid-liquid partitioning, and the ethyl acetate fraction is purified to a high purity, or the extract or fraction is subjected to chromatography such as column chromatography.
  • chromatography such as column chromatography.
  • An example is a method of purifying the.
  • As the chromatography, reverse phase column chromatography, normal phase thin layer chromatography and the like can be used.
  • Extraction or fraction of at least one compound selected from tureronol A and tureronol B, a plant or plant processed product containing the compound, or a plant or processed plant product containing the compound is dried, powdered by a conventional method It may be subjected to processing such as crystallization, granulation, or solution.
  • composition composition for inhibiting cancer cell growth composition for anticancer, composition for inhibiting canceration of normal cells, composition for inhibiting cancer development, composition for inducing cancer cell death
  • the first aspect of the present invention relates to a composition for inhibiting the growth of cancer cells, which contains at least one selected from tureronol A and tereronol B as an active ingredient.
  • the composition for suppressing the growth of cancer cells of the present invention is preferably a composition for suppressing the growth of colon cancer cells.
  • the first aspect of the present invention also relates to the use of at least one selected from tureronol A and turmeronol B for the production of a composition for inhibiting the growth of cancer cells.
  • the first aspect of the present invention also relates to the use of at least one selected from turmonol A and turmeronol B for the manufacture of a medicament for inhibiting the growth of cancer cells.
  • at least one selected from tureronol A and tureronol B is administered to a cancer cell in vivo or in vitro, and the growth of the cancer cell is suppressed.
  • the present invention relates to a method for suppressing the growth of cancer cells.
  • the first aspect of the present invention also relates to tureronol A, tureronol B, or a mixture of tureronol A and tureronol B for suppressing the growth of cancer cells in vivo or in vitro.
  • the second aspect of the present invention also includes administering at least one selected from tureronol A and tureronol B to a patient in need of treatment for cancer, and treating cancer in said patient. It relates to a method for treating cancer.
  • the second aspect of the present invention also relates to at least one selected from turmeronol A and tureronol B for treating cancer in a patient in need of cancer treatment.
  • the third aspect of the present invention relates to a composition for suppressing canceration of normal cells, containing as an active ingredient at least one selected from tureronol A and tereronol B.
  • the composition for suppressing canceration of normal cells of the present invention preferably suppresses canceration of normal cells to colon cancer.
  • the third aspect of the present invention also relates to the use of at least one selected from tureronol A and tereronol B for the production of a composition for suppressing canceration of normal cells.
  • the third aspect of the present invention also relates to the use of at least one selected from tureronol A and tureronol B for the manufacture of a medicament for inhibiting canceration of normal cells.
  • At least one selected from tureronol A and tureronol B is administered to normal cells in vivo or in vitro, and canceration of the normal cells is suppressed.
  • the present invention relates to a method for suppressing canceration of normal cells.
  • the third aspect of the present invention also relates to at least one selected from tureronol A and tureronol B for suppressing canceration of normal cells in vivo or in vitro.
  • the 4th aspect of this invention is related with the composition for cancer onset suppression containing as an active ingredient at least 1 sort (s) selected from termeronol A and turmeronol B.
  • the cancer onset suppression composition of the present invention is preferably a cancer onset suppression composition for colorectal cancer.
  • the fourth aspect of the present invention also relates to the use of at least one selected from tureronol A and tureronol B for the production of a cancer onset suppressing composition.
  • the fourth aspect of the present invention also relates to the use of at least one selected from tureronol A and tereronol B for the manufacture of a medicament for suppressing cancer onset.
  • At least one selected from tureronol A and tureronol B is administered to a patient in need of suppression of the onset of cancer, and the onset of cancer in the patient It is related with the method of suppressing onset of cancer including suppressing.
  • the fourth aspect of the present invention also relates to at least one selected from tureronol A and tureronol B for suppressing the onset of cancer in a patient in need of suppression of the onset of cancer.
  • the fifth aspect of the present invention relates to a composition for inducing cancer cell death, comprising at least one selected from tureronol A and tureronol B as an active ingredient.
  • the composition for inducing cancer cell death of the present invention is preferably a composition for inducing cell death of colorectal cancer cells.
  • the fifth aspect of the present invention also relates to a use for producing a composition for inducing cancer cell death, wherein at least one selected from termeronol A and turmeronol B is used.
  • the fifth aspect of the present invention also relates to the use of at least one selected from tureronol A and tereronol B for the manufacture of a medicament for inducing cancer cell death.
  • a fifth aspect of the present invention at least one selected from tureronol A and tereronol B is administered to a cancer cell in vivo or in vitro, and cell death of the cancer cell is induced.
  • the present invention relates to a method for inducing cell death of cancer cells.
  • the fifth aspect of the present invention also relates to at least one selected from tureronol A and turmeronol B for inducing cell death of cancer cells in vivo or in vitro.
  • the active ingredient used in the present invention or a composition or medicine containing the active ingredient may be a composition of each form such as a pharmaceutical, food and drink, feed, food additive, feed additive, etc., and is a pharmaceutical or food and drink. Is more preferable.
  • the foods and drinks include foods in the form of functional display foods, foods for specified health use, supplements for nutritional supplements, and the like.
  • the composition or medicament containing the active ingredient used in the present invention is preferably in the form of a composition taken or administered orally or nasally, more preferably in the form of a composition taken or administered orally. It is.
  • a composition or medicament comprising said compound is turmeronol A per daily intake or dose, preferably per human daily intake or dose, especially per adult. And at least 1 sort (s) selected from turmeronol A and turmeronol B is contained so that it may become 100 micrograms or more as a total amount of turmeronol B.
  • the composition or medicament comprising the active ingredient is per daily intake or dose, preferably per daily intake or dose for one human, especially one adult.
  • turmonol A and turmonol B Selected from turmonol A and turmonol B so that turmonol A is 80 ⁇ g or more and / or turmonol B is 20 ⁇ g or more, more preferably turmonol A is 80 ⁇ g or more and turmonol B is 20 ⁇ g or more.
  • a cancer cell growth inhibitory action, an anticancer action, a normal cell canceration inhibitory action, a cancer onset inhibitory action, or a cancer cell death inducing action can be effectively obtained.
  • “daily intake or dose” is typically 0.1 to 500 g as the amount of the composition of the present invention when taken or administered orally or nasally, preferably orally. is there.
  • the active ingredient used in the present invention or a composition or medicament containing the active ingredient may be ingested or administered continuously, or may be ingested or administered when necessary.
  • the active ingredient or a composition or medicament containing the active ingredient used in the present invention may be the active ingredient itself, or may contain the active ingredient and at least one other ingredient.
  • the active ingredient used in the present invention or a composition or medicine containing the active ingredient contains the active ingredient and at least one other ingredient, the active ingredient and at least one other ingredient are mixed. It may be a composition, or may be a composition in which the active ingredient and at least one other ingredient are formulated by an appropriate means, or the active ingredient and at least one other ingredient.
  • blended the component with the component may be mixed with the other component.
  • the shape of the active ingredient used in the present invention or the composition or medicament containing the active ingredient is not particularly limited, and may be any shape such as liquid, fluid, gel, semi-solid, or solid. Also good.
  • a pharmaceutical, food-drinks, feed, food additive, feed addition examples of components that are acceptable in the final form such as an agent and that can be taken orally can be given.
  • Such other components include sweeteners, acidulants, vitamins, minerals, thickeners, emulsifiers, antioxidants, and water.
  • Sweeteners include monosaccharides and disaccharides such as glucose, fructose, sucrose, lactose, maltose, palatinose, trehalose, and xylose, isomerized sugar (glucose fructose liquid sugar, fructose glucose liquid sugar, sugar mixed isomerized sugar, etc.) Sugar alcohols (erythritol, xylitol, lactitol, palatinit, sorbitol, reduced starch syrup, etc.), honey, high intensity sweeteners (sucralose, acesulfame potassium, thaumatin, stevia, aspartame, etc.).
  • sour agent examples include citric acid, malic acid, gluconic acid, tartaric acid, lactic acid, phosphoric acid, and salts thereof, and one or more of these can be used.
  • vitamins examples include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin E, niacin, inositol and the like.
  • Minerals include calcium, magnesium, zinc, iron and the like.
  • thickener examples include carrageenan, gellan gum, xanthan gum, gum arabic, tamarind gum, guar gum, locust bean gum, karaya gum, agar, gelatin, pectin, soybean polysaccharide, carboxymethylcellulose (CMC) and the like.
  • emulsifier examples include glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, lecithin, vegetable sterol, and saponin.
  • antioxidants examples include vitamin C, tocopherol (vitamin E), enzyme-treated rutin, catechin and the like.
  • compositions such as foods and drinks and pharmaceuticals.
  • compositions or pharmaceutical forms in which the active ingredient used in the present invention and at least one other ingredient are formulated by appropriate means are powders, granules, capsules, tablets (coated tablets or multilayer tablets such as sugar-coated tablets)
  • the composition may be in the form of a solid composition such as a disintegrating agent in the mouth, chewable tablets, etc., or in the form of a liquid composition such as a solution.
  • HT-29 cells a human colorectal cancer cell line
  • RPMI 1640 medium containing 10% FBS
  • the cells were cultured at 37 ° C. and 5% CO 2 for 24 hours.
  • HT-29 cells cultured in a 96-well plate in this manner were cultured in RPMI 1640 medium (containing 2.5% FBS) for 72 hours containing 12.5 ⁇ M, 25 ⁇ M, 50 ⁇ M, or 100 ⁇ M of either tereronol A or turmeronol B. Cultured.
  • WST-1 reagent was added 2 hours before the end of the culture, and the absorbance (metabolic activity of the cells) was measured with a plate reader after 2 hours.
  • HT-29 cultured in RPMI1640 medium containing each concentration of the sample was defined as 100% metabolic activity of HT-29 cells cultured in the same procedure except that RPMI1640 medium not containing specimens (termeronol A, turmeronol B) was used.
  • the change rate of the metabolic activity of 29 cells was determined.
  • the metabolic activity of a cell means a life-sustaining activity including cell proliferation activity and excessive activation.
  • FIG. 1 shows the results for tureronol A
  • FIG. 2 shows the results for tereronol B
  • FIG. 1 shows that treatment of HT-29 cells with turmeronol A significantly reduced the metabolic activity of the cells in a dose-dependent manner.
  • FIG. 2 shows that treatment of HT-29 cells with tureronol B significantly reduced the metabolic activity of the cells in a dose-dependent manner. From these results, it was shown that both turmeronol A and turmeronol B inhibit the metabolic activity of colon cancer cells.
  • the suppression of the metabolic activity of cancer cells as used herein means suppression of cancer cell growth, suppression of canceration, and induction of cancer cell death.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention aborde le problème de l'inhibition de la cancérisation de cellules et de la progression d'une altération maligne du cancer, c'est-à-dire, l'apparition d'un cancer, ou l'induction de la mort des cellules cancéreuses. La présente invention concerne une composition pour inhiber la prolifération de cellules cancéreuses, une composition anticancéreuse, une composition pour inhiber la cancérisation de cellules normales, une composition pour inhiber l'apparition d'un cancer, et une composition pour induire la mort des cellules cancéreuses, lesdites compositions comprenant chacune, en tant que principe actif, au moins un composé choisi parmi le Turméronol A et le Turméronol B.
PCT/JP2019/018555 2018-05-15 2019-05-09 Composition pour inhiber la prolifération de cellules cancéreuses, composition anticancéreuse, composition pour inhiber la cancérisation de cellules normales, composition pour inhiber l'apparition du cancer, et composition pour induire la mort de cellules cancéreuses WO2019221003A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020519595A JPWO2019221003A1 (ja) 2018-05-15 2019-05-09 がん細胞の増殖抑制用組成物、抗がん用組成物、正常細胞のがん化抑制用組成物、がん発症抑制用組成物、及び、がん細胞死誘導用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-093848 2018-05-15
JP2018093848 2018-05-15

Publications (1)

Publication Number Publication Date
WO2019221003A1 true WO2019221003A1 (fr) 2019-11-21

Family

ID=68539893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/018555 WO2019221003A1 (fr) 2018-05-15 2019-05-09 Composition pour inhiber la prolifération de cellules cancéreuses, composition anticancéreuse, composition pour inhiber la cancérisation de cellules normales, composition pour inhiber l'apparition du cancer, et composition pour induire la mort de cellules cancéreuses

Country Status (3)

Country Link
JP (1) JPWO2019221003A1 (fr)
TW (1) TW202003435A (fr)
WO (1) WO2019221003A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003342183A (ja) * 2002-05-30 2003-12-03 Okinawa Hakko Kagaku:Kk ウコンの抽出方法並びにウコン加工品
JP2007513176A (ja) * 2003-12-05 2007-05-24 ニュー・チャプター・インコーポレーテッド 前立腺癌を草本組成物で治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010260818A (ja) * 2009-05-07 2010-11-18 Picaso Cosmetic Laboratory Ltd チロシナーゼ阻害剤
JP2011116714A (ja) * 2009-12-04 2011-06-16 Tomoyuki Susa α−アミラーゼ阻害剤
WO2019198661A1 (fr) * 2018-04-09 2019-10-17 ハウスウェルネスフーズ株式会社 Composition d'inhibition de la prolifération de cellules cancéreuses, composition anti-cancéreuse, composition de prévention de la cancérisation de cellules normales, composition de prévention de l'apparition de cancer, et composition d'induction de la mort de cellules cancéreuses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003342183A (ja) * 2002-05-30 2003-12-03 Okinawa Hakko Kagaku:Kk ウコンの抽出方法並びにウコン加工品
JP2007513176A (ja) * 2003-12-05 2007-05-24 ニュー・チャプター・インコーポレーテッド 前立腺癌を草本組成物で治療する方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE PubMed [online] 5 June 2019 (2019-06-05), Database accession no. 26308760 *
DEL PRETE, D ET AL.: "Turmeric sesquitepenoids: Expeditious resolution, comparative bioactivity, and a new bicyclic turmeronoid", J NAT PROD, vol. 79, no. 2, 26 February 2016 (2016-02-26), pages 267 - 273, XP055644522, ISSN: 0163-3864, DOI: 10.1021/acs.jnatprod.5b00637 *
JAKSEVICIUS, A ET AL.: "Inhibitory effects of Culinary herbs and spices on the growth of HCA-7 colorectal cancer cells and their COX-2 expression", NUTRIENTS, vol. 9, no. 1051, 1 January 2017 (2017-01-01), pages 1 - 22, XP055644000, DOI: 10.3390/nu9101051 *
KANESHIRO, T ET AL.: "Growth inhibitory activities of crude extracts obtained from herbal plants in the Ryukyu island s on several human colon carcinoma cell lines", ASIAN PAC J CANCER PREV, vol. 6, no. 3, 2005, pages 353 - 358, XP055344221 *
KUKULA-KOCH W ET AL.: "Superior anticancer activity is demonstrated by total extract of Curcuma longa L. as opposed to individual curcuminoids separated by centrifugal partition chromatography", PHYTOTHER RES, vol. 32, no. 5, January 2018 (2018-01-01), pages 933 - 942, XP055644513, DOI: 10.1002/ptr.6035 *
SHEN, Y C ET AL.: "New sesquiterpenes from a Taiwan ese marine sponge of the genus parahigginsia", J CHIN CHEM SOC, vol. 46, no. 2, 1 April 1999 (1999-04-01), pages 201 - 204, XP055644521 *

Also Published As

Publication number Publication date
TW202003435A (zh) 2020-01-16
JPWO2019221003A1 (ja) 2021-05-27

Similar Documents

Publication Publication Date Title
KR102134307B1 (ko) 안토시아닌-후코이단 복합체를 유효성분으로 함유하는 면역증강제, 면역항암제 및 항암제 부작용 완화제
EP3461486B1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la démence et l'amélioration de la fonction cognitive, comprenant de l'acanthoside b issue d'un extrait de salicorne
WO2013015519A1 (fr) Composition antioxydante contenant un isorhamnétine-3-glucoside-7-rhamnoside séparé de feuilles d'hippophae rhamnoides à titre de principe actif
WO2019198661A1 (fr) Composition d'inhibition de la prolifération de cellules cancéreuses, composition anti-cancéreuse, composition de prévention de la cancérisation de cellules normales, composition de prévention de l'apparition de cancer, et composition d'induction de la mort de cellules cancéreuses
WO2019221003A1 (fr) Composition pour inhiber la prolifération de cellules cancéreuses, composition anticancéreuse, composition pour inhiber la cancérisation de cellules normales, composition pour inhiber l'apparition du cancer, et composition pour induire la mort de cellules cancéreuses
CN114126594B (zh) 用于抑制TNF-α或IL-6产生的组合物
WO2018207910A1 (fr) Composition anti-inflammatoire
KR20190142672A (ko) 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물
JP6835396B2 (ja) 血中グルコース濃度低減用、血中ヘモグロビンＡ１ｃ量低減用又は血中ＨＤＬ−コレステロール量増加用組成物
KR20110070624A (ko) 뉴라미니데이즈 억제활성을 가지는 들깨 추출물
KR20180088606A (ko) 비알코올성 지방간 질환 예방 또는 치료능이 있는 이소람네틴(isorhamnetin)을 함유하는 퉁퉁마디(Salicornia SPP.) 물 추출물의 에틸아세테이트 분획물
JP2017160129A (ja) 抗悪性腫瘍組成物
KR102069125B1 (ko) 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물
KR101068990B1 (ko) 개느삼 추출물, 개느삼 분획물, 이로부터 분리한 개느사논 ｈ 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 항암제용 약학적 조성물
JP2018521073A (ja) ジゴキシンの微粉化に関する非機械的プロセス
JP5016200B2 (ja) アカシア属樹皮由来物を含有する腫瘍の予防及び／又は治療用組成物
WO2020261538A1 (fr) Composition permettant d'abaisser la pression artérielle
US20220378720A1 (en) Composition for Improving or Maintaining Quality of Life
JP2024000684A (ja) 細胞多様性と複雑な組織構造を保持したがん組織の治療剤
JP2004194554A (ja) 健康食品
JP2022072006A (ja) アドレノメデュリン遺伝子発現増強用組成物
CN103877274A (zh) 一种瑞香狼毒提取物粉针剂
WO2008012089A2 (fr) Composition à base de polyphénol et de peptide
KR20180000703A (ko) 비알코올성 지방간 질환 예방 또는 치료능이 있는 이소람네틴 및 염화나트륨을 함유하는 퉁퉁마디 추출물
KR20180021642A (ko) 2-알콕시-6-아세틸-7-메틸주글론을 유효성분으로 함유하는 항헬리코박터 파이로리 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19804499

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020519595

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19804499

Country of ref document: EP

Kind code of ref document: A1